Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma

Inclusion Criteria:

* Subjects with hematologically or pathohistologically diagnosed peripheral T/NK-cell lymphoma
* Subjects who have been positive for CCR4
* Subjects who received one or more chemotherapy regimens
* Subjects who relapse after achieving complete response, uncertain complete response or partial response by the last chemotherapy
* Subjects who have an interval of 4 weeks or more between the last day of the prior therapy and the scheduled day of the first KW-0761 treatment
* Subjects with nodal lesions, extranodal lesions and/or cutaneous lesions
* Subjects who have a performance status of 0 to 2
* Subjects who are negative for HBs antigen and reported as "not detected" for HBV-DNA
* Subjects who are negative for anti-HCV antibody
* Subjects who have normal function of the major organs
* Subjects who have given written voluntary informed consent to participate in the study

Exclusion Criteria:

* Subjects who underwent transplant therapy such as hematopoietic stem-cell transplantation (Subjects who underwent autologous hematopoietic stem-cell transplantation following chemotherapy will not be excluded)
* Subjects who are known carriers of HIV
* Subjects who have active multiple cancer
* Subjects who have a history of allergic reactions to therapeutic antibodies
* Subjects requiring continuous systemic treatment with steroid
* Subjects who require emergency radiotherapy for treating the symptoms caused by bulky masses at enrollment or who may require such radiotherapy after the start of the study
* Subjects who are pregnant, lactating or of childbearing potential, or who are planning to have children